<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02030769</url>
  </required_header>
  <id_info>
    <org_study_id>20130925-4</org_study_id>
    <nct_id>NCT02030769</nct_id>
  </id_info>
  <brief_title>Pronase Improves Efficacy of Chromoendoscopy Screening on Esophageal Cancer</brief_title>
  <official_title>Pronase Improves Efficacy of Chromoendoscopy Screening on Esophageal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xijing Hospital of Digestive Diseases</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Tide Pharmaceutical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Xijing Hospital of Digestive Diseases</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Lugol's solution staining was regarded as a gold standard to detect early superficial lesion
      during esophageal cancer screening using endoscopy. However, the sensitivity and specificity
      were influenced by mucus and food debris of esophagus. Pronase, a kind of protease, was
      previously shown to improve the visibility of gastrointestinal tract. It's unknown if the
      pre-treatment with pronase would also improve the quality of iodine staining in esophagus.A
      randomized double-blind clinical trial was designed to investigate whether or not pronase
      might improve detection rate of early esophageal lesion, especially high grade dysplasia and
      early cancer by improving the esophageal visibility.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Detection rate of high grade dysplasia and carcinoma in iodine void lesion</measure>
    <time_frame>1 week</time_frame>
    <description>Detection Rate=（lesions with confirmed high grade dysplasia/all iodine void lesions）*100%</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Average Esophageal Visibility Score Before iodine staining</measure>
    <time_frame>30 min after ingesting pretreatment solution</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Esophageal Visibility Score After iodine staining</measure>
    <time_frame>within 5 min after iodine staining</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detection Rate of lesions with pink sign</measure>
    <time_frame>within 5 min after iodine staining</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall detection rate of iodine void lesion</measure>
    <time_frame>within 5 min after iodine staining</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>observation time for esophagus</measure>
    <time_frame>with 30 min after intubation</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1000</enrollment>
  <condition>Esophageal Neoplasms</condition>
  <arm_group>
    <arm_group_label>Pronase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Add pronase 20000 U in 80ml pretreatment mixture plus 5ml Dimethicone and 1g sodium bicarbonate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>No pronase in 80ml pretreatment mixture plus 5ml Dimethicone and 1g sodium bicarbonate.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pronase</intervention_name>
    <description>use pronase to improve visibility during endoscopical iodine staining</description>
    <arm_group_label>Pronase</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>No pronase plus Dimethicone and sodium bicarbonate. use without pronase to compare visibility during endoscopical iodiine staining</description>
    <arm_group_label>control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients 60 years to 75 years old

          -  Patients less than 60 years old, but with one or multiple high risk factors for
             esophageal cancer including smoking and drinking addiction,family history of
             esophageal cancer, personal history of esophageal or head and neck malignancies,
             previous endoscopy documenting iodine void superficial lesion.

        Exclusion Criteria:

          -  Allergy to iodine or any other medicine which used in this trial.

          -  Previous endoscopy revealing advanced esophageal cancer or other non-superficial
             lesions.

          -  Conditions interfering visibility of endoscope including gastrointestinal obstruction
             and upper gastrointestinal bleeding.

          -  Anatomic variation by surgery.

          -  Pregnancy

          -  Other conditions which investigator consider the patient at high risk for
             complications.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kaichun Wu, Ph.D. &amp; M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Xijing Hospital of Digestive DIsease</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Xijing Hospital of Digestive Disease</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Lopes AB, Fagundes RB. Esophageal squamous cell carcinoma - precursor lesions and early diagnosis. World J Gastrointest Endosc. 2012 Jan 16;4(1):9-16. doi: 10.4253/wjge.v4.i1.9.</citation>
    <PMID>22267978</PMID>
  </reference>
  <reference>
    <citation>Yokoyama A, Hirota T, Omori T, Yokoyama T, Kawakubo H, Matsui T, Mizukami T, Mori S, Sugiura H, Maruyama K. Development of squamous neoplasia in esophageal iodine-unstained lesions and the alcohol and aldehyde dehydrogenase genotypes of Japanese alcoholic men. Int J Cancer. 2012 Jun 15;130(12):2949-60. doi: 10.1002/ijc.26296. Epub 2011 Sep 16.</citation>
    <PMID>21796615</PMID>
  </reference>
  <reference>
    <citation>Dubuc J, Legoux J-, Winnock M, Seyrig J-, Barbier J-, Barrioz T, Laugier R, Boulay G, Grasset D, Sautereau D, Grigoresco D, Butel J, Scoazec J-, Ponchon T; Société Française d'Endoscopie Digestive. Endoscopic screening for esophageal squamous-cell carcinoma in high-risk patients: a prospective study conducted in 62 French endoscopy centers. Endoscopy. 2006 Jul;38(7):690-5.</citation>
    <PMID>16874909</PMID>
  </reference>
  <reference>
    <citation>Ishihara R, Yamada T, Iishi H, Kato M, Yamamoto S, Yamamoto S, Masuda E, Tatsumi K, Takeuchi Y, Higashino K, Uedo N, Tatsuta M, Ishiguro S. Quantitative analysis of the color change after iodine staining for diagnosing esophageal high-grade intraepithelial neoplasia and invasive cancer. Gastrointest Endosc. 2009 Feb;69(2):213-8. doi: 10.1016/j.gie.2008.04.052. Epub 2008 Aug 20.</citation>
    <PMID>18718584</PMID>
  </reference>
  <reference>
    <citation>Shimizu Y, Omori T, Yokoyama A, Yoshida T, Hirota J, Ono Y, Yamamoto J, Kato M, Asaka M. Endoscopic diagnosis of early squamous neoplasia of the esophagus with iodine staining: high-grade intra-epithelial neoplasia turns pink within a few minutes. J Gastroenterol Hepatol. 2008 Apr;23(4):546-50. Epub 2007 Jun 15.</citation>
    <PMID>17573830</PMID>
  </reference>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 6, 2014</study_first_submitted>
  <study_first_submitted_qc>January 8, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2014</study_first_posted>
  <last_update_submitted>March 28, 2016</last_update_submitted>
  <last_update_submitted_qc>March 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Xijing Hospital of Digestive Diseases</investigator_affiliation>
    <investigator_full_name>Zhiguo Liu</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Esophageal Neoplasms</keyword>
  <keyword>Lugol's solution</keyword>
  <keyword>Pronase</keyword>
  <keyword>Endoscopy, Digestive System</keyword>
  <keyword>Pretreatment method</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

